Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of GIOTRIF is substantial in the first-line therapy of locally advanced or metastatic non-small cell lung cancer with activating EGFR mutation(s).
|
Clinical Added Value
| no clinical added value |
GIOTRIF provides no improvement in actual benefit (level V, non-existent) in the first-line therapy of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
|
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
vNhyAxeQckCSec2q